# Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

> **NCT07717450** · PHASE3 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 370 (estimated)

## Conditions studied

- Metastatic Invasive Breast Cancer

## Interventions

- **PROCEDURE:** Tumor assessment
- **OTHER:** Completion of Quality-of-life questionnaires
- **PROCEDURE:** ECG
- **PROCEDURE:** Visual Acuity assessment

## Key facts

- **NCT ID:** NCT07717450
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-25
- **Primary completion:** 2032-06-25
- **Final completion:** 2032-06-25
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-07-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717450, "Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*